Shares of BioTelemetry Inc. (NASDAQ:BEAT) were down 3.4% on Friday . The stock traded as low as $20.57 and last traded at $20.58, with a volume of 129,983 shares trading hands. The stock had previously closed at $21.30.

Several analysts have recently weighed in on BEAT shares. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research note on Thursday, August 4th. Benchmark Co. lifted their price target on shares of BioTelemetry from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, August 3rd.

The firm has a market capitalization of $591.61 million and a price-to-earnings ratio of 44.91. The stock’s 50 day moving average is $18.81 and its 200-day moving average is $14.75.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, August 2nd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.17 by $0.03. The firm earned $52.68 million during the quarter, compared to analysts’ expectations of $50.27 million. During the same period in the prior year, the company earned $0.12 EPS. The firm’s quarterly revenue was up 17.6% compared to the same quarter last year. On average, analysts forecast that BioTelemetry Inc. will post $0.76 earnings per share for the current year.

A hedge fund recently raised its stake in BioTelemetry stock. Russell Frank Co increased its position in shares of BioTelemetry Inc. (NASDAQ:BEAT) by 58.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 249,457 shares of the company’s stock after buying an additional 92,455 shares during the period. Russell Frank Co owned approximately 0.92% of BioTelemetry worth $2,933,000 at the end of the most recent reporting period.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.